Transtuzumab‐DM1 and Brentuximab Vedotin (anti‐CD30 conjugated to MMAE) are Food and Drug Administration (FDA)‐approved ADCs to treat breast cancers and Hodgkin's lymphoma, respectively (Pillay et al., 2011; Weiner, 2015). This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.